運用藥效基團集虛擬篩選以探索表皮生長因子受體抑制劑之新化學結構

Abstract

肺癌的死亡率占所有癌症死亡率中的第一位，以非小細胞肺癌為主， 因為發現不易，且發現時已接近晚期，治療不易，傳統上是以不具選擇性 的癌症化療藥物來治療，但副作用大，治療的成效也不理想。表皮生長因 子受體在很多固癌裡有過度表現的情形，而在非小細胞肺癌的病人中也有 40∼80﹪會過度表現，因此被視為一藥物設計的重要標的。在2003 年， 美國的FDA 通過了第一個以表皮細胞生長因子受體蛋白酪氨酸激酶抑制 劑，可對體細胞的突變（取代白氨酸為精氨酸）L858R，在亞洲地區病人， 女性，不吸癌者有顯著良好的治療結果，然而此類藥物在施予幾個月後病 人皆會發展出抗藥性。鑒於新型藥物開發的迫切性，我們的目標是運用高 計算效率的藥效基團比對，對六百萬化合物資料庫進行篩選，以尋找不同 化學骨架的L858R 抑制劑。

Lung cancer is the first mortality rate of all carcinoma. The major part is Non--‐Small--‐Cell Lung Cancer(NSC--‐LC). The curative effect is not ideal for not easily diagnosis and almost in the late state when the tumor was discovered. Pharmacotherapy of lung cancer traditionally is by chemotherapy, but the adverse effect is serious and the curative effect is not ideal. Epidermal growth factor receptor (EGFR), is over--‐expresed in many solid tumor including the non--‐small--‐cell lung cancer (NSC--‐LC) (40~80%). In 2003, the first epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib) was approved by food and drug administration (FDA) in America. Dramatic therapeutic effect was discovered in Asia patient, non--‐smoker and women and is highly related to EGFR L858R (substitution of leucine 858 to arginine). However, drug resistance is occurred in several months after administration of this kind ofdrug. For the imperious demand of the new drug development, our goal is to discovery different scaffold EGFR L858R inhibitor (other than 4-anilinoquinazoline of gefitinib) by using the high performance pharmacophore based virtual screening to six million chemical database.